This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the UW Paul P. Carbone Comprehensive Cancer Center (UWCCC). Over the past 30 years, the UWCCC has maintained exemplary main institution accrual and strong affiliate participation while providing high quality data and key scientific leadership. Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative, and scientific leadership. The basic, translational, and clinical research programs of the UWCCC are designed to reduce the cancer burden on the population by improving prevention, early detection, and treatment of cancer. The UWCCC commitment to cancer care and research has never been stronger. During the current grant cycle, we have tripled our clinical space and doubled our research space, representing an institutional commitment of nearly $100 million, and increased our cancer focused faculty by nearly 50%. The UWCCC faculty views the NCI cooperative groups as essential components in the war on cancer. Translation of scientific discovery to human populations and to individual patients requires an ability to conduct large scale clinical trials in a timely fashion. ECOG provides this vital forum and the UWCCC remains highly committed to its mutually beneficial partnership with ECOG.

Public Health Relevance

ECOG clinical trials are a vitally important cancer treatment option for the citizens of Wisconsin. Group trials represent a proven system for improving outcomes for patients affected by cancer and the University of Wisconsin and its ECOG affiliates remain enthusiastic participants in the cooperative group system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA021076-38
Application #
8465828
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2014-02-28
Budget Start
2013-05-01
Budget End
2014-02-28
Support Year
38
Fiscal Year
2013
Total Cost
$496,942
Indirect Cost
$162,301
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Perez Horta, Zulmarie; Goldberg, Jacob L; Sondel, Paul M (2016) Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8:1097-117
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wang, Wei; Erbe, Amy K; Gallenberger, Mikayla et al. (2016) Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother 65:1523-1532
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004

Showing the most recent 10 out of 181 publications